The administration of the recommended doses of Filgrastim is commonly associated with medullary bone pain generally reported to be of mild to moderate severity and could be controlled in most patients with non-narcotic analgesics at conventional doses. Mild to moderate dysuria and transient decreases in blood pressure are the secondary effects less frequently reported ad do not require treatment. Spontaneously reversible and dose dependent elevations in uric acid, lactate dehydrogenase and alkaline phosphatase occurred during FILGRASTIM (LEUCOGEN) therapy. White blood cell counts of 100,000/mm3
or greater were observed in cancer patients receiving Filgrastim at doses above 3 mcg/kg/day. There were no reports of adverse effects associated to chemotherapy: Nausea, vomiting, alopecia, diarrhea, anorexia, fever, fatigue, mucositis, headache, constipation, skin rash, cough and thoracic pain are not increased in patients receiving Filgrastim treatment. There have been rare reports of cutaneous vasculitis in patients treated with Filgrastim. Symptoms of vasculitis generally developed simultaneously with an increase in the absolute neutrophils counts.